Curaleaf just took its Aurora Cannabis buyout public — and hostile

Curaleaf took its bid for Aurora Cannabis directly to shareholders on August 11 after the Canadian producer's board repeatedly declined to negotiate. The terms: an implied $4 per share, capped at $5, paid as 0.3463 Curaleaf subordinate voting shares plus $0.75 cash for every Aurora share — a 45% premium over Aurora's 30-day volume-weighted average price, or 110% once you strip out the cash already sitting on Aurora's balance sheet. Aurora shares jumped 22% to $3.48 the day the offer went public.

The appeal is Aurora's European medical footprint: roughly 50 metric tons a year of EU-GMP cultivation and manufacturing capacity, including the recently acquired Safari Flower Company. A combined Curaleaf-Aurora would operate in 17 countries with about $1.5 billion in trailing revenue, close to $350 million in adjusted EBITDA, and a targeted $40 million in annual cost synergies.

Aurora's board hasn't said yes or no — it's formed a special committee of independent directors and says it's weighing the offer against other strategic alternatives, which is corporate-speak for stalling while it figures out if a better bid is out there.

The bigger signal: after two years dominated by MSO bankruptcies, receiverships and grow-house closures, a large, cash-generating US operator is going on offense instead of playing defense. That's a different posture than the market's gotten used to, and it puts every other undervalued cross-border operator — Canopy Growth included, per the speculation already circulating — on notice as a potential target.

For operators watching from the sidelines, the read is simple: balance-sheet strength is starting to translate into acquisition power again, not just survival. If this deal closes, expect more MSOs with clean balance sheets to start hunting rather than just holding the line.